Endocrine Abstracts

Background: Biochemical biomarker DT is used clinically for prognosis prediction in several solid malignancies. The aim of the current analysis was to determine whether biomarker DT has any prognostic utility in patients with NETs.Methods: Patients with NETs (n=184) were enrolled in a prospective study with comprehensive biochemical analysis. The current analysis included subjects with increasing 5-HIAA levels in at least two consecutive measure...

Background: About 8–20% of patients with von Hippel-Lindau disease (vHLd) develop pancreatic neuroendocrine tumors (PNETs). However, prognostic markers for these tumors are lacking. The VHL gene mutation type is associated with the clinical phenotype of vHLd. Hence, we aimed to determine whether VHL mutation characteristics may be associated with PNETs phenotype in patients with vHLd.Methods: A prospective study of patients with vHLd and PNETs with ...

Background: Patients with neuroendocrine tumors (NETs) have divergent survival, even when having the same site of primary tumor, and tumor stage and grade. 68Gallium (68Ga)-DOTATATE positron emission tomography (PET)/computed tomography (CT) is a sensitive imaging modality for detecting NETs. The purpose of this study was to determine whether 68Ga-DOTATATE PET/CT imaging has any prognostic utility in patients with NETs.Methods: One hundred and eighty-fou...